Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis M Weiner

Showing results (31-40 of 133) with videos related to

Pageof 14
Sort By:
Cell|March 20, 2012
Antibody-based immunotherapy of cancerLouis M Weiner, Joseph C Murray, Casey W Shuptrine
The Lancet. Oncology|December 8, 2016
Predictive biomarkers for checkpoint inhibitor-based immunotherapyGeoffrey T Gibney, Louis M Weiner, Michael B Atkins
Methods in Cell Biology|February 13, 2026
Assays to examine lymphocyte invasionAlexander A Lekan, Rachael E Maynard, Louis M Weiner
Transplantation and Cellular Therapy|July 5, 2022
The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer CellsJake Moscarelli, David Zahavi, Rachael Maynard, et al.
Annual Review of Medicine|January 15, 2003
Monoclonal antibody therapy for cancerMargaret von Mehren, Gregory P Adams, Louis M Weiner
Cancer|December 13, 2006
Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumorsRobert A Beckman, Louis M Weiner, Hugh M Davis
Antibody Therapeutics|April 30, 2021
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapyDavid Zahavi, Dalal AlDeghaither, Allison O'Connell, et al.
Biomarkers in Medicine|May 19, 2010
Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug developmentSandra Urtishak, R Katherine Alpaugh, Louis M Weiner, et al.
Seminars in Cancer Biology|December 24, 2019
Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodiesReham Ajina, David J Zahavi, Yong-Wei Zhang, et al.
Cancer Immunology Research|September 11, 2014
IL4 limits the efficacy of tumor-targeted antibody therapy in a murine modelRishi Surana, Shangzi Wang, Wei Xu, et al.
Pageof 14

Showing results (31-40 of 133) with videos related to

Sort By:
Pageof 14
Cell|March 20, 2012
Antibody-based immunotherapy of cancerLouis M Weiner, Joseph C Murray, Casey W Shuptrine
The Lancet. Oncology|December 8, 2016
Predictive biomarkers for checkpoint inhibitor-based immunotherapyGeoffrey T Gibney, Louis M Weiner, Michael B Atkins
Methods in Cell Biology|February 13, 2026
Assays to examine lymphocyte invasionAlexander A Lekan, Rachael E Maynard, Louis M Weiner
Transplantation and Cellular Therapy|July 5, 2022
The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer CellsJake Moscarelli, David Zahavi, Rachael Maynard, et al.
Annual Review of Medicine|January 15, 2003
Monoclonal antibody therapy for cancerMargaret von Mehren, Gregory P Adams, Louis M Weiner
Cancer|December 13, 2006
Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumorsRobert A Beckman, Louis M Weiner, Hugh M Davis
Antibody Therapeutics|April 30, 2021
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapyDavid Zahavi, Dalal AlDeghaither, Allison O'Connell, et al.
Biomarkers in Medicine|May 19, 2010
Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug developmentSandra Urtishak, R Katherine Alpaugh, Louis M Weiner, et al.
Seminars in Cancer Biology|December 24, 2019
Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodiesReham Ajina, David J Zahavi, Yong-Wei Zhang, et al.
Cancer Immunology Research|September 11, 2014
IL4 limits the efficacy of tumor-targeted antibody therapy in a murine modelRishi Surana, Shangzi Wang, Wei Xu, et al.
Pageof 14